Welcome to our dedicated page for Kailera Therapeutics SEC filings (Ticker: KLRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Kailera Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Kailera Therapeutics's regulatory disclosures and financial reporting.
Kailera Therapeutics director and 10% owner Adam Koppel, through an affiliated fund, reported a large net share increase. On April 20, 2026, an entity associated with him made an open-market purchase of 1,562,500 shares of Common Stock at $16.00 per share, bringing its reported Common Stock holdings to 22,583,268 shares held indirectly.
The filing also shows automatic conversions of 16,875,000 shares of Series A-1 Preferred Stock and 4,145,768 shares of Series B Preferred Stock into Common Stock on a 1:1 basis upon the closing of Kailera’s initial public offering, eliminating those preferred positions. Separately, on April 16, 2026, Dr. Koppel received a grant of stock options for 38,300 shares at an exercise price of $16.00, vesting fully on April 16, 2027.
Kailera Therapeutics, Inc. reported that investment entities affiliated with Bain Capital Life Sciences increased their indirect stake. BCLS Fund IV Investments, L.P. bought 1,562,500 shares of common stock in an open-market purchase at $16.00 per share.
On the same date, BCLS Fund IV Investments, L.P. also acquired additional common stock through automatic 1:1 conversions of Series A-1 and Series B Preferred Stock upon the closing of Kailera’s initial public offering. After these transactions, BCLS Fund IV Investments, L.P. indirectly held 22,583,268 shares of Kailera common stock.
BCPE Perseus Investor, LP, an entity associated with Kailera Therapeutics, Inc. director and 10% owner Andrew T. Kaplan, bought 8,398,438 shares of Kailera Therapeutics common stock at $16.00 per share on April 20, 2026 in an open-market transaction reported as indirect ownership.
On the same date, 17,857,143 shares of Series B Preferred Stock held by BCPE Perseus automatically converted into an equal number of common shares on a 1:1 basis upon the closing of Kailera’s initial public offering. Following these transactions, BCPE Perseus is reported as indirectly holding 26,255,581 common shares, while Kaplan also received a direct grant of stock options for 38,300 shares at a $16.00 exercise price that vest on April 16, 2027. Kaplan disclaims beneficial ownership of BCPE Perseus’ holdings except to the extent of his pecuniary interest.
Kailera Therapeutics Chief People Officer Paula Cloghessy reported two grants of stock options, each covering 60,000 shares of common stock at an exercise price of $16.00 per share, expiring on April 16, 2036.
One option grant vests 25% of the shares on April 16, 2027, then in 36 substantially equal monthly installments, contingent on continued service. The second grant vests, if at all, only if the stock reaches $40 per share during a 30-day average or in a qualifying change in control between October 16, 2026 and April 16, 2030, also requiring continued service.
Kailera Therapeutics, Inc. reported that Chief Legal Officer Scott Akamine received two grants of stock options, each covering 60,000 shares of common stock at an exercise price of $16.00 per share, as compensation awards.
One 60,000-share option vests over time, with 25% vesting on April 16, 2027 and the remainder in 36 monthly installments, subject to continued service. The second 60,000-share option vests only if the company’s stock reaches at least $40 per share during a defined performance period or in a qualifying change in control, also requiring continued service.
Kailera Therapeutics, Inc. director, CEO & President Ronald C. Renaud Jr. was granted stock options linked to the company’s common stock. The Form 4 shows two awards of stock options, each covering 300,000 shares at an exercise price of $16.00 per share, expiring on April 16, 2036.
One option grant vests 25% on April 16, 2027 and then in 36 equal monthly installments, as long as he continues in service. The second grant vests only if the stock reaches $40 per share during a defined performance period or in a qualifying change in control, also requiring continued service through vesting.
Kailera Therapeutics reported that officer Paul D. Burgess received two grants of stock options, each covering 100,000 shares of common stock at an exercise price of $16.00 per share. These are compensation awards, not open‑market purchases.
One option grant vests over time, with 25% vesting on April 16, 2027 and the remainder in 36 equal monthly installments, subject to continued service. The second grant vests only if the company’s stock price reaches $40 during a defined performance period or in a qualifying change in control, with both awards expiring on April 16, 2036.
Kailera Therapeutics, Inc. reported that director John F. Milligan received a grant of stock options covering 38,300 shares of common stock. The options have an exercise price of $16.00 per share and expire on April 16, 2036.
The options vest and become exercisable in full on April 16, 2027, as long as Milligan continues to serve the company through that date. Following this grant, he holds stock options for 38,300 underlying shares directly.
Kailera Therapeutics, Inc. reported that Chief Commercial Officer Jamie Beth Coleman received two stock option awards, each covering 75,000 shares of common stock at an exercise price of $16 per share.
One option vests 25% on April 16, 2027 and then in 36 equal monthly installments, conditioned on continued service. The second option vests only if, during the period from October 16, 2026 to April 16, 2030, the company’s stock trades at or above $40 per share for 30 consecutive trading days or reaches at least $40 per share in a qualifying change in control, also subject to continued service.
Kailera Therapeutics director Martin Mackay received a new stock option grant. On April 16, 2026, he was granted options to acquire 38,300 shares of Common Stock at an exercise price of $16.00 per share.
The options were granted as compensation, not through an open‑market purchase or sale, and are held directly. They vest and become exercisable for 100% of the underlying shares on April 16, 2027, subject to his continued service. Following this grant, he holds 38,300 stock options, which expire on April 16, 2036.